REG - MicroSalt PLC - Notice of Investor Presentation 9th June 2025

MicroSaltAnnouncement

02/06/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250602:nRSB9037Ka&default-theme=true

RNS Number : 9037K  MicroSalt PLC  02 June 2025

2 June 2025

 

 
MicroSalt plc

 

 
("MicroSalt" or the "Company")

 

 

Notice of Investor Presentation via Investor Meet Company

 

MicroSalt plc, (AIM: SALT), a leading manufacturer of full flavour salt with
approximately 50% less sodium is pleased to announce that following the
announcement of the Final Results for the year ended 31 December 2024, Rick
Guiney (CEO) and Konrad Dabrowski (CFO) will hold a live presentation on the
Company via the Investor Meet Company platform on 9 June 2025 at 5.30p.m. GMT.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9.00a.m. GMT on 6 June 2025 or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to
meet MicroSalt plc via:

https://www.investormeetcompany.com/microsalt-plc/register
(https://www.investormeetcompany.com/microsalt-plc/register)

 

Investors who already follow MicroSalt plc on the Investor Meet Company
platform will automatically be invited.

 

 For more information, please visit www.microsaltinc.co
(http://www.microsaltinc.co) , follow on X @microSaltPLC or contact:

 

 MicroSalt plc                                                 Via Flagstaff PR
 Rick Guiney, CEO

 Zeus (Nominated adviser and broker)                           +44 (0)20 3829 5000
 David Foreman, James Edis (Investment Banking)

 Flagstaff PR (Financial PR)                                   +44 (0)20 7129 1474
 Tim Thompson / Alison Allfrey / Anna Probert

 microsalt@flagstaffcomms.com

( )

 

About MicroSalt®

 

MicroSalt® produces a patented full-flavour, low-sodium salt for food
manufacturers and consumers.

 

MicroSalt is a major potential disruptor in the food market, thanks to its
micron sized particles which deliver the same sense of saltiness to a wide
range of foods but with approximately 50% less sodium. Excess sodium
consumption is a significant contributor to cardiovascular disease and
MicroSalt's solution meets the rising demand for healthier alternatives to
traditional salt. The WHO has set a target for reducing global sodium intake
by 30% by 2025, which it estimates will save 7 million lives by 2030.

 

Each year, cardiovascular disease costs the UK £19 billion - if the average
salt intake was reduced by one gram per day, it has been estimated that 4,147
lives and £288 million would be saved each year in the UK. As a nation, the
UK consumes 183 million kilograms of salt each year, and 70 per cent. of the
typical person's sodium intake is hidden in processed foods.

 

Operational since 2018, MicroSalt uses patent-protected technology which helps
create high barriers to entry within the reduced-sodium salt market. The group
has a US patent and 14 patent applications pending in other jurisdictions
globally.

 

The Directors believe that MicroSalt is well positioned to capture growth in
the low sodium market, which is expected to grow exponentially, and that there
is also potential to enter the larger salt market.

 

 

ENDS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPUPAQUPAGMG